Eli Lilly has set 2025 as the launch year for its anti-obesity drugs, with Mounjaro at the forefront of its weight loss portfolio. Mounjaro is going up against Trulicity, both drugs are made by Eli Lilly and are approved to treat type 2 diabetes as weekly injections. In the SURPASS-CVOT trial, Mounjaro achieved non-inferiority to Trulicity in the prevention of major cardiovascular events (MACE-3) with an 8% lower risk (HR: 0.92).[3][7] Mounjaro reduced overall mortality by 16% (HR: 0.84).[3][7][8] Patients on Mounjaro lost an average of 25 pounds (11.3 kg) over three years versus 10 pounds (4.5 kg) on Trulicity, with better A1C control and kidney function.[7] Side effects were mild to moderate gastrointestinal symptoms, with discontinuation in 13.3% of patients on Mounjaro and 10.2% on Trulicity.[3] The results of the study will be presented at EASD 2025 and submitted to regulatory authorities by the end of the year.[3]